The James J. Peters Veterans Hospital in Bronx, New York, is actively
recruiting participants for a phase IIb clinical trial testing NIC5-15,
a disease modifying candidate for Alzheimer's disease.
Humanetics Corporation has developed the use of NIC5-15 in collaboration
with Mount Sinai School of Medicine's Alzheimer's Disease Research
Center (ADRC), a comprehensive clinical program and research facility.
The US Patent and Trademark Office issued a patent for the use of
NIC5-15 in June. Humanetics has exclusively licensed the patent through
MSSM's Office of Technology and Business Development.
NIC5-15 has been shown in preclinical studies and animal models to be
effective in preventing the formation of beta-amyloid plaques, which are
believed to be a leading cause of Alzheimer's disease. Multiple clinical
studies in non-Alzheimer's populations have demonstrated the safety and
phamacokinetics of NIC5-15.
Washington University School of Medicine joins collaboration to improve pediatric heart disease care